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ABSTRACT 
 
Background: Breast cancer is the most common type of cancer suffered by women in the 
world. The combination of tamoxifen and chemotherapy significantly reduces the risk of recur-
rence and mortality in breast cancer patients. This study aimed to analyze how effective the com-
bination of tamoxifen and chemotherapy after surgery to reduce the risk of recurrence and 
mortality in breast cancer patients with positive hormone receptor. 
Subjects and Method: This study used systematic review and meta-analysis. The researcher 
collected articles from the Pubmed journal database. The subjects of the study were women with 
breast cancer after surgery. The dependent variable was recurrence and survival (mortality). The 
independent variables were tamoxifen and chemotherapy. Data were analyzed based on the fixed 
and random effects model using RevMan 5 software. 
Results: There were 3 articles with 3,761 women who were involved in the analysis process. The 
combination of tamoxifen and chemotherapy could reduce the risk of recurrence in women with 
positive hormone receptor (ER+) breast cancer (HR=0.68; 95%CI=0.58 to 0.80; p=0.001). The 
combination of tamoxifen and chemotherapy showed weak and non-significant decreasing trend in 
reducing the risk of mortality in women with ER+breast cancer (HR=0.87; 95%CI=0.73 to 1.03; p= 
0.11). 
 Conclusion: The combination of tamoxifen and chemotherapy in women with ER+ breast cancer 
is effective in reducing the risk of recurrence. However, it does not increase survival. 
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BACKGROUND 
Breast cancer is the most common type of 
cancer suffered by women in the world. 
Breast cancer is ranking first in African, 
Europe, and Asia continents with the 
highest mortality rate in women (IARC, 
2018). Breast cancer is also the largest 
number type of cancer with the second 
largest number of new cases (11.6%) after 
lung cancer in the world (Bray et al., 2018). 
Breast cancer is the type of cancer that 
causes the most common deaths in Indo-
nesia with the total number of 19,731 in 
2014 (Listyawardhani et al., 2018). Adju-
vant therapy such as chemotherapy and 
hormonal therapy is often recommended by 
oncologists as a treatment for breast cancer 
(Cloud and Esfahani, 2018) 
Chemotherapy has an important role 
in the last two decades. It is a treatment for 
breast cancer in reducing tumor mass 
before surgery. In addition, it prevents the  
tumor for coming back after surgery 
(EBCTCG, 2012; Akram and Siddiqui, 
2012).  
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Tamoxifen has been extensively 
studied and proven effective for treating 
early-stage breast cancer (Jankowitz and 
Davidson, 2013). The combination of tamo-
xifen and chemotherapy can increase sur-
vival by reducing the risk of mortality and 
recurrence (Bramwell et al., 2010). 
This study aimed to compare the 
effectiveness of the combination of chemo-
therapy with tamoxifen and the effective-
ness of chemotherapy only to reduce the 
risk of recurrence and improve survival in 
women with breast cancer with positive 
hormone receptor. 
 
SUBJECTS AND METHOD 
1. Design of the Study 
This study used systematic review and 
meta-analysis design. It referred to the 
Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses guidelines 
(PRISMA). The researcher collected articles 
from the Pubmed journal database using 
the keywords such as "tamoxifen", "chemo-
therapy", and "breast cancer". 
2. Inclusion Criteria 
The inclusion criteria were: 1) Intervention 
was a combination of tamoxifen and 
standard chemotherapy; 2) Control was 
chemotherapy only; 3) The design of the 
study was RCT; 3) The articles used English 
language; 4) The results of the study were 
recurrence and survival. 
3. Population and Sample 
The population of the study was women 
with breast cancer of ER+ type who had 
undergone surgery (mastectomy). This 
study involved 4 clinical trials with 3761 
women as the subjects of the study.  
4. Variables of the Study 
The dependent variable was the combina-
tion of recurrence and survival. The inde-
pendent variables were the combination of 
chemotherapy and hormonal.  
5. Operational Definition of Variables 
Intervention of this study was the combina-
tion of chemotherapy and tamoxifen. Con-
trol was chemotherapy. Recurrence was the 
second cancer cell after the intervention. 
Survival was the death occurred due to all 
causes after the intervention. 
6. Data Analysis 
The data were analyzed using RevMan 5. 
The data were described using the effect 
size hazard ratio with 95% confidence inter-
val (CI). The value of p<0.05 indicated that 
the result was statistically significant. 
 
RESULT 
After searching for the articles in Pubmed 
database, 336 articles were found.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Research Flow  
Articles identified through database 
search (n= 336) 
The excluded articles  
(n= 333) 
 They were not RCT studies 
 The intervention was not the combination 
of tamoxifen and chemotherapy 
 The control was not chemotherapy only 
 The results were not recurrence and 
survival  
 Measure of effect was not hazard ratio  
Full-text articles that were considered 
appropriate (n= 3) 
Full-text articles involved in the 
quantitative synthesis (n= 3) 
Full-text articles involved in the 
qualitative synthesis (n= 3) 
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There were 333 articles that were excluded 
because they did not meet the inclusion cri-
teria. There were 3 full text articles in quan-
titative and qualitative analysis (Figure 1). 
There were 3 articles in the analysis of the 
variable of recurrence (Table 1) and 3 arti-
cles on the variable of survival (Table 2). 
The intervention followed the operational 
standards for chemotherapy and tamoxifen 
that were used globally (Table 3). 
Table 1. The result of the study on the variable of recurrence in each article analyzed. 
No Writer Total number of 
patients 
Total number of 
recurrence (n) 
Hazard 
Ratio 
95% CI p 
1 Bramwell (2010) Intervention= 252 
Control= 253 
Total=505 
Intervention = 252 
Control = 253 
0.82 0.61-1.11 0.18 
2 Morales (2006) Intervention = 233 
Control = 258 
Total= 491 
Intervention = 233 
Control = 258 
0.68 0.50-0.93 0.014 
 
3 International Breast 
Cancer Study Group 
(2006) 
Intervention = 365 
Control = 370 
Total= 735 
Intervention =108 
Control =164 
0.59 0.46-0.75 0.001 
 
Table 2. The result of the study on the variable of survival in each article analyzed. 
No Writer Total number of 
patients 
Total number of 
mortality (n) 
Hazard 
Ratio 
95% CI p 
1 Bramwell (2010) Intervention =252 
Control = 253 
Total= 672 
Intervention = 252 
Control = 253 
0.83 0.58-1.18 0.12 
2 Morales (2006) Intervention = 
233 
Control = 258 
Total= 491 
Intervention = 233 
Control = 258 
0.89 0.69-1.15 0.001 
 
3 International Breast 
Cancer Study Group 
(2006) 
Intervention = 365 
Control = 370 
Total= 735 
Intervention =68 
Control =78 
0.86 0.62-1.19 0.36 
 
Table 3. The specifications of the therapy given to each article analyzed. 
No Writer Therapy in the intervention 
group  
Therapy in the 
control group 
Duration of therapy 
1 Andersson 
(1999) 
 9 cycles of the CMF. 
 30 mg of tamoxifen a day 
 9 cycles of the 
CMF. 
Chemotherapy and 
hormonal therapy were 
given for 1 year.  
2 Bramwell 
(2010) 
 6 CMF. 
 6 cycles of the CEF. 
 4 cycles of the AC. 
 20 mg tablet of ta-
moxifen.  
 6 cycles of the 
CMF. 
 6 cycles of the 
CEF. 
 4 cycles of the AC. 
 Placebo. 
Chemotherapy was given 
for 14 weeks. 
Tamoxifen was given on 
the 8th day of the 
chemotherapy for 5 
years. 
 3 Hutchins 
(2005) 
 6 cycles of the CMF. 
 6 cycles of the CAF. 
 20 mg tablet of tamo-
xifen. 
• 6 cycles of the CMF 
• 6 cycles of the CAF 
Tamoxifen was given on 
the 29th day in the cycles 
of chemotherapy. 
4 International 
Breast Can-
cer Study 
Group 
(2006) 
 Doxorubicin, cyclophos-
phamide, methotrexate, 
fluorouracil. 
 Epirubicin, cyclophos-
phamide, methotrexate, 
• Doxorubicin, cy-
clophosphamide, 
methotrexate, flu-
orouracil. 
 Epirubicin, cyclo-
Chemotherapy was given 
for 21 days, then it was 
given again after 28 days 
since the first therapy. 
Tamoxifen was given 
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fluorouracil. 
 20 mg tablet of tamo-
xifen. 
phosphamide, me-
thotrexate, fluoro-
uracil. 
after the cycle of 
chemotherapy was 
complete, for 5 years. 
5 Morales 
(2006) 
 6 CMF. 
 4-6 cycles of CAF, CEF, 
FAC or FEC. 
 20 mg tablet of tamoxifen 
• 6 CMF 
•4-6 cycles CAF, 
CEF, FAC atau 
FEC. 
Tamoxifen was given in 
the last 2 weeks of the 
cycle of chemotherapy, 
for 3 years. 
6 Ingle (1989)  10 cycles CFP.  
 10 mg tamoxifen 2 times 
a day. 
 10 cycles CFP.  
 
Chemotherapy and 
tamoxifen were 
conducted for 6 weeks. 
7 Tormey 
(1990) 
 CMF. 
 CMFP. 
 10 mg of tamoxifen 2 
times a day. 
 CMFP. Chemotherapy and 
tamoxifen were 
conducted for 28 days. 
 
1. Recurrence 
a. Forest Plot 
The combination of chemotherapy conti-
nued with tamoxifen showed the significant 
result compared to chemotherapy only in 
reducing the risk of recurrence in women 
with breast cancer with positive hormone 
receptor (HR=0.68; 95%CI=0.58 to 0.80; 
p= 0.001) (Figure 2). Based on the result of 
the analysis, the value of heterogeneity 
obtained was low (I2=28%). Therefore, a 
fixed effect model was used. 
 
 
 
 
 
 
 
 
 
Figure 2. Forest plot of recurrence as the variable  
b. Funnel Plot 
The funnel plot on recurrence showed that 
there was a publication bias on the analysis. 
It was indicated by the asymmetrical 
location of the circles on the right and left 
sides of the line. The small circles 
represented each article in the analysis 
(Figure 3). 
 
 
 
 
 
 
 
 
 
 
Figure 3. Funnel plot of recurrence as the variable 
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2. Survival 
a. Forest Plot 
The comparison between the combination 
of chemotherapy and tamoxifen did not 
show the significant result compared with 
chemotherapy only in improving survival 
by reducing mortality in women with breast 
cancer with positive hormone receptor 
(HR=0.87; 95%CI=0.73 to 1.03; p=0.11) 
(Figure 4). Based on the result of the 
analysis, the value of heterogeneity was 
very low (I2=0%). Therefore, a fixed effect 
model was used. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Forest plot of survival as the variable 
 
b. Funnel Plot 
Funnel plot on survival showed that there 
was no publication bias on the result of 
the analysis. It was indicated by the 
circles location that was in the diameter 
symmetrically (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Funnel plot of survival as the variable 
 
DISCUSSION 
Based on the global data, breast cancer is 
the most common type of cancer experi-
enced by women (Yu et al., 2017). Accord-
ing to Burstein et al. (2014), the most 
common type of breast cancer is positive 
hormone receptor (60-75%). Positive hor-
mone receptor is the breast cancer with 
positive estrogen receptor (ER+) or positive 
progesterone receptor (PR+) (Tang et al., 
2016).  
Chemotherapy aims to reduce tumor 
mass before surgery and prevent tumor for 
coming back after surgery. It is caused by 
HIF-1α which is more commonly found 
(hypoxia triggering factors) in cancerous 
tissue after chemotherapy than before 
chemotherapy (Berman, 2015; Wiraswesty 
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et al., 2016; Ruihua et al., 2017). Tamoxifen 
has been extensively studied and proven 
effective for treating breast cancer. Based 
on a meta-analysis study, the use of tamo-
xifen for 5 years in breast cancer patients 
with ER- had a positive significant effect in 
reducing the risk of recurrence within the 
first 10 years. In addition, it decreased 
almost one-third the mortality rate within 
the first 15 years. It occurred due to the 
antitumor effect on tamoxifen. How the 
amoxifen's system work is by blocking 
estrogen hormone receptor in breast tumor, 
thus reducing the circulation of the hor-
mone estrogen in breast tissue which is 
useful for inhibiting the growth of can-
cerous tissue (Davies et al., 2011; Jankowitz 
and Davidson, 2013; Rubin, 2015). 
Giving tamoxifen after chemotherapy 
increased the cure rate of breast cancer 
patients who had positive endocrine recep-
tor (ER+). Giving tamoxifen for 3 years 
after chemotherapy had benefit towards the 
recurrence and survival in breast cancer 
with positive hormone receptor. Tamoxifen 
has benefits on the breast cancer with posi-
tive receptor hormone, except the breast 
cancer with negative receptor hormone 
(Morales et al., 2006; International Breast 
Cancer Study Group, 2015; Hutchins et al., 
2015). 
Based on the result of the analysis, the 
combination of chemotherapy and hor-
monal was more effective than chemothe-
rapy only in reducing recurrence towards 
breast cancer (HR=0.68; 95%CI= 0.58 to 
0.80). This result was statistically signifi-
cant (p=0.001). It had a low heterogeneity 
value (I2=28%), so that the analysis used 
fixed effect model. This is in accordance 
with a study conducted by EBCTCG (2012) 
that both therapies (chemo and endocrine) 
could increase disease free survival by 
reducing the risk of recurrence. 
Based on the result of the analysis, the 
combination of chemotherapy and hor-
monal was more effective than chemothe-
rapy only in reducing mortality, thus in-
creasing survival in breast cancer (HR= 
0.87; 95%CI=0.58 to 0.80). This result was 
statistically non-significant (p=0.11) and 
had low heterogeneity value (I2=0%), so 
that the analysis used fixed effect model. 
The result is in accordance with a study 
conducted by Fisher et al. (2001) that the 
combination of chemotherapy continued 
with tamoxifen had less significant effect in 
reducing the risk of mortality in breast 
cancer. 
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